Ruxolitinib by Apotex: Understanding the Active Ingredients and Similar Substances

As a medication, Ruxolitinib by Apotex is a JAK inhibitor used to treat myelofibrosis and polycythemia vera. In this article, we will delve into the active ingredients of Ruxolitinib by Apotex and explore other substances that are similar in composition and function.

What is Ruxolitinib by Apotex?

Ruxolitinib by Apotex is a medication that contains the active ingredient Ruxolitinib, which is a Janus kinase (JAK) inhibitor. JAK inhibitors are a class of medications that block the activity of Janus kinases, enzymes that play a crucial role in the signaling pathways that regulate inflammation and immune responses.

Active Ingredients of Ruxolitinib by Apotex

The active ingredient of Ruxolitinib by Apotex is Ruxolitinib, which is a small molecule that inhibits the activity of JAK1 and JAK2 enzymes. The chemical name of Ruxolitinib is N-(4-(2-Hydroxyethyl)phenyl)-2-(4-(2-hydroxyethyl)phenyl)-5-(4-pyridinyl)-1H-imidazole-4-carboxamide.

Other Substances in Ruxolitinib by Apotex

In addition to Ruxolitinib, Ruxolitinib by Apotex contains several inactive ingredients, including:

* Lactose monohydrate: a sugar that is commonly used as an excipient in pharmaceutical formulations.
* Microcrystalline cellulose: a type of cellulose that is used as a filler and binder in tablets.
* Silica colloidal anhydrous: a type of silica that is used as an anti-caking agent.
* Magnesium stearate: a type of stearate that is used as a lubricant and anti-caking agent.
* Hypromellose: a type of cellulose that is used as a binder and coating agent.

Similar Substances to Ruxolitinib

Several other substances have a similar composition and function to Ruxolitinib. Some of these substances include:

* Baricitinib: a JAK inhibitor that is used to treat rheumatoid arthritis.
* Tofacitinib: a JAK inhibitor that is used to treat rheumatoid arthritis and psoriatic arthritis.
* Upadacitinib: a JAK inhibitor that is used to treat rheumatoid arthritis.
* Fedratinib: a JAK2 inhibitor that is used to treat myelofibrosis.

Patent Information for Ruxolitinib by Apotex

According to DrugPatentWatch.com, the patent for Ruxolitinib by Apotex is held by Incyte Corporation and is set to expire in 2028. The patent was granted in 2013 and covers the use of Ruxolitinib to treat myelofibrosis and polycythemia vera.

Conclusion

In conclusion, Ruxolitinib by Apotex is a medication that contains the active ingredient Ruxolitinib, a JAK inhibitor that is used to treat myelofibrosis and polycythemia vera. The medication also contains several inactive ingredients, including lactose monohydrate, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate, and hypromellose. Several other substances have a similar composition and function to Ruxolitinib, including baricitinib, tofacitinib, upadacitinib, and fedratinib.

Key Takeaways

* Ruxolitinib by Apotex is a medication that contains the active ingredient Ruxolitinib, a JAK inhibitor.
* The medication is used to treat myelofibrosis and polycythemia vera.
* The patent for Ruxolitinib by Apotex is held by Incyte Corporation and is set to expire in 2028.
* Several other substances have a similar composition and function to Ruxolitinib, including baricitinib, tofacitinib, upadacitinib, and fedratinib.

FAQs

1. What is Ruxolitinib by Apotex used to treat?
Ruxolitinib by Apotex is used to treat myelofibrosis and polycythemia vera.
2. What is the active ingredient of Ruxolitinib by Apotex?
The active ingredient of Ruxolitinib by Apotex is Ruxolitinib, a JAK inhibitor.
3. What are the inactive ingredients of Ruxolitinib by Apotex?
The inactive ingredients of Ruxolitinib by Apotex include lactose monohydrate, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate, and hypromellose.
4. What is the patent status of Ruxolitinib by Apotex?
The patent for Ruxolitinib by Apotex is held by Incyte Corporation and is set to expire in 2028.
5. What are some similar substances to Ruxolitinib?
Some similar substances to Ruxolitinib include baricitinib, tofacitinib, upadacitinib, and fedratinib.

Sources

1. DrugPatentWatch.com. (2022). Ruxolitinib by Apotex. Retrieved from <https://www.drugpatentwatch.com/drug/ruxolitinib-apotex>
2. Incyte Corporation. (2013). Ruxolitinib. Retrieved from <https://www.incyte.com/products/ruxolitinib>
3. National Institutes of Health. (2022). Ruxolitinib. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23314292>
4. European Medicines Agency. (2022). Ruxolitinib. Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/jakafi>
5. World Health Organization. (2022). Ruxolitinib. Retrieved from <https://www.who.int/medicines/access/essentialmedicines/en/ruxolitinib>